Novavax, Inc. develops vaccines to combat serious infectious diseases using a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant. The company focuses on urgent health challenges like COVID-19, influenza, and malaria. It commercializes a COVID-19 vaccine for adult and adolescent populations as well as booster indications. Novavax also develops an R21/Matrix-M adjuvant malaria vaccine.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | 22.2% |
| Net Debt/EBITDA | 1.9 |